Zentalis Pharmaceuticals (NASDAQ:ZNTL) Research Coverage Started at William Blair

William Blair initiated coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report sent to investors on Wednesday morning, Marketbeat reports. The brokerage issued an outperform rating on the stock.

Several other analysts also recently weighed in on the company. Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price target on the stock. Wall Street Zen cut Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Finally, Mizuho initiated coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.75.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $3.11 on Wednesday. Zentalis Pharmaceuticals has a 1 year low of $1.21 and a 1 year high of $6.95. The stock has a market cap of $222.89 million, a P/E ratio of -1.59 and a beta of 1.85. The firm has a 50-day moving average of $4.14 and a 200 day moving average of $3.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). Research analysts expect that Zentalis Pharmaceuticals will post -2.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Group Walters acquired 4,335,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the transaction, the insider directly owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ZNTL. Spark Investment Management LLC bought a new position in Zentalis Pharmaceuticals in the second quarter valued at about $61,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at about $126,000. Stonepine Capital Management LLC bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at about $783,678. Seven Fleet Capital Management LP increased its position in shares of Zentalis Pharmaceuticals by 188.7% during the 2nd quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock valued at $1,451,000 after purchasing an additional 207,600 shares during the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at about $5,406,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to address biological mechanisms involved in tumor growth, resistance to treatment and disease progression.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral, selective WEE1 kinase inhibitor. The company is evaluating azenosertib in clinical studies involving solid tumors and hematologic malignancies, including ovarian cancer, uterine serous carcinoma and other cancers.